Oxytocin intranasal - Vyera Pharmaceuticals

Drug Profile

Oxytocin intranasal - Vyera Pharmaceuticals

Alternative Names: Syntocinon Nasal Spray; TUR 001

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Retrophin; Turing Pharmaceuticals; University of California, San Diego
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder; Lactation failure; Schizophrenia

Most Recent Events

  • 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals (Vyera Pharmaceuticals California Comprehensive Compliance Program, September 2017)
  • 15 Feb 2017 Discontinued - Clinical-Phase-Unknown for Schizophrenia (Adjunctive treatment) in USA (Intranasal)
  • 15 Feb 2017 Discontinued - Phase-II for Lactation failure in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top